Evidence map›Paper›PMID 37175696›Full record

ArticleInternational journal of molecular sciences2023

CRISPR/Cas9 and

Valentina Muto, Federica Benigni, Valentina Magliocca, Rossella Borghi, Elisabetta Flex, Valentina Pallottini, Alessandro Rosa, Claudia Compagnucci, Marco Tartaglia

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Valentina MutoMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.
Federica BenigniMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.
Valentina MaglioccaMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.ORCID 0000-0002-9439-3794
Rossella BorghiMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.
Elisabetta FlexDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Valentina PallottiniDepartment of Science, University Roma Tre, 00146 Rome, Italy.ORCID 0000-0003-2511-6168
Alessandro RosaDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0001-9999-7223
Claudia CompagnucciMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.ORCID 0000-0003-0877-6172
Marco TartagliaMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.ORCID 0000-0001-7736-9672
Bambino Gesù Children's Hospital · ITRoma Tre University · ITIstituto Superiore di Sanità · ITItalian Institute of Technology · IT

Funding

Fondazione Bambino Gesù Vite CoraggioseItalian Ministry of Health Ricerca 2019 5 × 1000Italian Ministry of Health Ricerca Finalizzata Giovani Ricercatori GR-2019-12368907
6 · The paper itself

Abstract

Induced pluripotent stem cells (iPSCs) have been established as a reliable in vitro disease model system and represent a particularly informative tool when animal models are not available or do not recapitulate the human pathophenotype. The recognized limit in using this technology is linked to some degree of variability in the behavior of the individual patient-derived clones. The development of CRISPR/Cas9-based gene editing solves this drawback by obtaining isogenic iPSCs in which the genetic lesion is corrected, allowing a straightforward comparison with the parental patient-derived iPSC lines. Here, we report the generation of a footprint-free isogenic cell line of patient-derived

Indexed as

CRISPR-Cas SystemsInduced Pluripotent Stem CellsAnimalsCell DifferentiationEndophenotypesGene EditingHumansMicrotubule-Associated ProteinsMutationMicrotubule-Associated ProteinsTBCD protein, humanCRISPR/Cas9 technologygene editingiPSCsisogenic controlsneurodevelopmental disorderPEBATTBCD

Identifiers

PMID37175696
PMCPMC10178052
OpenAlexW4367315908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.